56 results
8-K
EX-99.2
NVRO
Nevro Corp
7 Jan 19
Results of Operations and Financial Condition
9:10am
LEADERSHIP THROUGH INNOVATION J.P. Morgan 37th Annual Healthcare Conference January 2019 Exhibit 99.2
SPECIAL NOTE REGARDING FORWARD-LOOKING … $387.1 IPO November U.S. Launch June $69.6 $228.5 $326.7 $65.4 Track Record of Execution
Continued Product Innovation Senza II Launched Smaller, refined
8-K
EX-99.1
NVRO
Nevro Corp
18 Dec 19
Nevro Appoints Karen N. Prange to the Company’s Board of Directors
7:15am
management roles, Ms. Prange has extensive experience in commercial and operational roles, including managing innovation pipelines and acquiring
8-K
EX-99.1
NVRO
Nevro Corp
1 Aug 22
Other Events
7:11am
, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 80,000 patients globally. Nevro’s comprehensive HFX™ spinal cord
8-K
EX-99.1
NVRO
Nevro Corp
3 Dec 20
Nevro Announces Director Appointment
7:12am
companies large and small to adopt them for growth. Most recently, at General Electric, she held the positions of Chief Innovation Officer for GE and CEO
8-K
EX-99.1
NVRO
Nevro Corp
7 May 24
Nevro Reports First-Quarter 2024 Financial Results
4:11pm
. In addition to his current responsibilities, which include leading the company’s manufacturing processes and innovation, research and development … patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic innovation that has impacted
8-K
EX-99.1
z4gczds0x1e no8
21 Feb 24
Nevro Enters Into Cooperation Agreement With Engaged Capital
4:11pm
8-K
EX-99.1
ddfzfqclg9r
1 Dec 23
Nevro Announces Acquisition of Vyrsa™ Technologies
6:07am
8-K
EX-99.1
z1ufaw
10 Jan 22
Nevro Announces Preliminary, Unaudited Fourth Quarter and Fourth Quarter 2021 Worldwide Revenue of Approximately $102.5 Million
6:12am
8-K
EX-99.1
6xadb8
9 Jan 24
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
8:41am
8-K
EX-99.1
25j9zxy
19 Apr 23
Results of Operations and Financial Condition
5:07pm
8-K
EX-99.1
pns55t
26 Apr 23
Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance
4:13pm
8-K
EX-99.1
21qup6c7wn85csxd7x
1 Aug 23
Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance
4:10pm
8-K
EX-99.1
s5g4y wth
23 Feb 22
Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance
12:00am
8-K
EX-99.1
da2lyiawshk stjep
1 Nov 23
Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance
4:07pm
8-K
EX-99.1
z3co7s70yqer3 kn
4 May 22
Nevro Reports First Quarter 2022 Financial Results, Provides Second Quarter 2022 Guidance and Reiterates Full-Year 2022 Guidance
4:18pm
8-K
EX-99.1
23wb 3p8fp
2 Nov 22
Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy
4:14pm
8-K
EX-99.1
zehr0m4
21 Feb 24
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
4:09pm
8-K
EX-99.1
gd06s8
3 Aug 22
Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance
4:18pm